



The K-321-303 Study

A clinical study for patients with cataracts and Fuchs Endothelial Corneal Dystrophy

As someone living with Fuchs Endothelial Corneal Dystrophy (FECD) and cataracts, you may be interested in learning about the **K-321-303 Study**, a clinical trial investigating a new therapy designed to help treat FECD.

What is the purpose of the study?

Researchers are looking for better ways to correct visual difficulties of patients living with FECD. Current treatments for FECD include a procedure known as Descemet Stripping Only (DSO), during which the damaged tissue is stripped away. Once the diseased area is removed from the cornea, the patient's own healthy cells move from the outer edges of the cornea to the center. A new investigational medicine called ripasudil (K-321) may help speed up healing and recovery of vision after cataract surgery and DSO.

What happens during the study?

This study lasts about a year and has four parts: screening, cataract surgery and DSO procedure, treatment, and follow-up. There are 15 study visits in total.



What is the treatment?

The drug being studied is ripasudil ophthalmic solution 0.4% (K-321). It is administered as an eye drop. In several studies, K-321 has been found to help wounds heal faster and improve vision in FECD patients undergoing DSO alone.

Patients will be randomly assigned to one of these treatment groups:

K-321 — 4 times daily

Placebo (no active ingredient) — 4 times daily

Neither you nor the study doctor will know which study drug you are using. If you would like to learn more about the K-321-303 Study, please contact:

Site	Location	Physician	Contact Phone Number	Study Coordinator	Study Coordinator Phone Number
Verdier Eye Center	Grand Rapids, Michigan	David Verdier	(616) 949-2001	Devon Keeler	(616) 949-2001 x1111
Keck Hospital of USC	Los Angeles, California	Jun-Min Martin Heur	(800) 872-2273	Mariana Edwards	(323) 442-6490
Precision Cornea Centre	Ottawa, Ontario	Kashif Baig	(613) 746-2244	Andrew Samuel	(161) 374-6224 x4
Dr. Greg Moloney	Vancouver, British Columbia	Gregory Moloney	N/A	Yumi Ohashi	(604) 875-8889
Prism Eye Institute - Mississauga-Oakville	Oakville, Ontario	Joshua Teichman	(905) 456-3937	Elif Demircan	(905) 456-3937 x267
Bascom Palmer Eye Institute	Palm Beach Gardens, Florida	Ellen Koo	(561) 355-8974	Olufemi Sangoyomi	(561) 355-8985
Macy Eye Center	Los Angeles, California	Jonathan Macy	(310) 657-2777	Scott Kaesemeyer	(310) 657-2777
University of Kentucky	Lexington, Kentucky	Seema Capoor	(859) 218-2627	Renee James	(859) 323-5868
Houston Eye Associates	Houston, Texas	John Goosey	(713) 558-8777	Alicia Guerra	(713) 558-8777
R and R Eye Research, LLC.	San Antonio, Texas	Gregory Brunin	(210) 424-2584	Gustavo Chapa	(210) 340-1212
Vance Thompson Vision West Fargo	West Fargo, North Dakota	Michael Greenwood	(701) 566-5390	Alyson Saville	(701) 809-9905
Vance Thompson Vision - Omaha	Omaha, Nebraska	Brandon Baartman	(402) 347-4680	Sarah Harnett	(402) 899-8020
University Hospitals Cleveland Medical Center	Cleveland, Ohio	Ahmed Farghaly Abdelh	(216) 844-3601	Sangeetha Raghupathy	(216) 844-8552
Gorovoy MD Eye Specialists	Fort Myers, Florida	Mark Gorovoy	(239) 939-1444	Carrie Soto	(239) 284-1688
W Kellogg Eye Center	Ann Arbor, Michigan	Shahzad Mian	(734) 763-8122	Lianne Shami	(734) 764-4048
Eye Associates of New Mexico - Albuquerque	Albuquerque, New Mexico	Kenneth Himmel	(505) 888-5757	Darlene Harbour	(505) 393-7483
Byers Eye Institute at Stanford	Palo Alto, California	Charles Lin	(650) 497-7935	Zachary Wennberg-Smith	(650) 497-5942
Devers Eye Institute	Portland, Oregon	Michael Straiko	(503) 413-8032	Alex Bauer	(503) 413-8032
University of Texas Southwestern Medical Center	Dallas, Texas	Venkateswara Vinod Mod	(214) 648-3111	Daphne Fuerte	(214) 645-2012
Sacramento Eye Consultants	Sacramento, California	Patricia Sierra	(916) 649-1515	Madelyn Pownceby	(916) 649-1515 xext250
Cincinnati Eye Institute-1945 Cei Dr	Cincinnati, Ohio	Michael Nordlund	(513) 984-5133	Lee Stokes	(513) 569-3213